Security: Series C Preferred
Location: Berkeley, CA
President: Bill Newell
Executive VP, COO: Rick Fuller
VP, Principal Financial Officer: Tony Rimac
New Investors: Clarus Ventures, Alta Partners
Existing Investors: Apax Partners, Lehman Brothers, NGN Capital, Burrill & Co.
Board of Directors: Farah Champsi, Lee Douglas, Nick Galakatos, Hingge Hsu, Mark Perry, John Walker

- Aerovance is a company that is focused on the development and commercialization of biologics for respiratory and inflammatory diseases.

- The company is a spinout of Bayer.

- The $60 million financing is structured in two tranches: $28 million at first closing in May 2006 and $32 million at second closing in March 2007 following completion of milestones.